BioCentury
ARTICLE | Clinical News

Menveo regulatory update

February 20, 2012 8:00 AM UTC

Novartis said it received a complete response letter from FDA for an sBLA for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2 months to 2 years. Novartis said FDA asked for additional data but the company did not disclose details. ...